

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2762029

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	MATTHEW DOUGLAS BREYER	03/05/2014
	LING LIU	03/05/2014
	ZHONGHUA QI	03/05/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	Eli Lilly and Company	
<b>Street Address:</b>	Lilly Corporate Center	
<b>Internal Address:</b>	Patent Division	
<b>City:</b>	Indianapolis	
<b>State/Country:</b>	INDIANA	
<b>Postal Code:</b>	46285	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	14203675
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(317)276-3861	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	patents@lilly.com	
<b>Correspondent Name:</b>	ELI LILLY AND COMPANY	
<b>Address Line 1:</b>	P. O. BOX 6288	
<b>Address Line 2:</b>	PATENT DIVISION	
<b>Address Line 4:</b>	INDIANAPOLIS, INDIANA 46206-6288	
<b>ATTORNEY DOCKET NUMBER:</b>	X19929	
<b>NAME OF SUBMITTER:</b>	LINDA M. DURBIN	
<b>SIGNATURE:</b>	/Linda M. Durbin/	
<b>DATE SIGNED:</b>	03/11/2014	
<b>Total Attachments: 6</b>		
source=X19929AssignmentBreyer#page1.tif		
source=X19929AssignmentBreyer#page2.tif		
source=X19929AssignmentLiu#page1.tif		

source=X19929AssignmentLiu#page2.tif

source=X19929AssignmentQi#page1.tif

source=X19929AssignmentQi#page2.tif

**ASSIGNMENT****WHEREAS, I**

Matthew Douglas Breyer, Indianapolis, IN, Citizenship: United States

am a co-inventor of an invention that is the subject of a patent application ("Application") which is entitled THERAPEUTIC USES FOR VEGFR1 ANTIBODIES for filing:

☒ in the United States Patent and Trademark Office on Mar. 11, 2014  
and accorded Serial Number 14/203675,

☐ in the \_\_\_\_\_ on \_\_\_\_\_  
and accorded Serial Number \_\_\_\_\_,

☐ in the Spanish Patent Office as a European Application on \_\_\_\_\_  
and accorded Serial Number \_\_\_\_\_,

☒ as an international application under the Patent Cooperation Treaty ("PCT"),  
with United States Patent and Trademark Office acting as Receiving Office on  
Mar. 11, 2014 and accorded Serial Number PCT/US2014/022925

☐ as an international application under the Patent Cooperation Treaty ("PCT"),  
with The State Intellectual Property Office (SIPO) of China acting as Receiving  
Office on \_\_\_\_\_ and accorded Serial Number  
\_\_\_\_\_,

both of which claim the benefit of priority application Serial Number 61/788870  
filed March 15, 2013.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

**WHEREAS ELI LILLY AND COMPANY**, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

**NOW, THEREFORE**, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all

of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

3/5/14  
Date

Matthew D Breyer  
Matthew Douglas Breyer

**ASSIGNMENT****WHEREAS, I**

Ling Liu, Carmel, IN, Citizenship: United States

am a co-inventor of an invention that is the subject of a patent application ("Application") which is entitled THERAPEUTIC USES FOR VEGFR1 ANTIBODIES for filing:

☒ in the United States Patent and Trademark Office on Mar. 11, 2014  
and accorded Serial Number 14/203675,

☐ in the \_\_\_\_\_ on \_\_\_\_\_  
and accorded Serial Number \_\_\_\_\_,

☐ in the Spanish Patent Office as a European Application on \_\_\_\_\_  
and accorded Serial Number \_\_\_\_\_,

☒ as an international application under the Patent Cooperation Treaty ("PCT"),  
with United States Patent and Trademark Office acting as Receiving Office on  
Mar. 11, 2014 and accorded Serial Number PCT/US2014/022925

☐ as an international application under the Patent Cooperation Treaty ("PCT"),  
with The State Intellectual Property Office (SIPO) of China acting as Receiving  
Office on \_\_\_\_\_ and accorded Serial Number  
\_\_\_\_\_,

both of which claim the benefit of priority application Serial Number 61/788870  
filed March 15, 2013.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

**WHEREAS ELI LILLY AND COMPANY**, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

**NOW, THEREFORE**, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all

of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

03-05-14  
Date

  
Ling Liu

**ASSIGNMENT****WHEREAS, I**

Zhonghua Qi, Carmel, IN, Citizenship: China

am a co-inventor of an invention that is the subject of a patent application ("Application") which is entitled THERAPEUTIC USES FOR VEGFR1 ANTIBODIES for filing:

☒ in the United States Patent and Trademark Office on Mar. 11, 2014  
and accorded Serial Number 14/203675,

☐ in the \_\_\_\_\_ on \_\_\_\_\_  
and accorded Serial Number \_\_\_\_\_,

☐ in the Spanish Patent Office as a European Application on \_\_\_\_\_  
and accorded Serial Number \_\_\_\_\_,

☒ as an international application under the Patent Cooperation Treaty ("PCT"),  
with United States Patent and Trademark Office acting as Receiving Office on  
Mar. 11, 2014 and accorded Serial Number PCT/US2014/022925

☐ as an international application under the Patent Cooperation Treaty ("PCT"),  
with The State Intellectual Property Office (SIPO) of China acting as Receiving  
Office on \_\_\_\_\_ and accorded Serial Number  
\_\_\_\_\_.

both of which claim the benefit of priority application Serial Number 61/788870  
filed March 15, 2013.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

**WHEREAS ELI LILLY AND COMPANY**, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

**NOW, THEREFORE**, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all

of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

3/5/2014

Date



Zhonghua Qi